Precision Optics Corporation, Inc. (POCI) does not attract broad analyst attention. A single firm, Lucid Capital Markets, started coverage on May 18, 2026, with a Buy rating and an $8.00 objective, describing the company as an undervalued growth name in medical and defense optics. With only one published target available, the $8 level here draws from that source plus the stock’s earlier peak near $7.85 rather than any averaged consensus. It functions as a reference point anchored to both the published call and a prior technical high, and readers should treat it with that single-source limitation in mind. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares trade near $4.97, roughly midway in a 52-week range of $3.55 to $6.15. Closing the gap to $8 would mean an advance of about 61%, a sizable move for any micro-cap with a market value around $50 million. The route would likely involve first reclaiming the 52-week high near $6.15, then surpassing the all-time high near $7.85. On the fundamentals side, that would call for turning strong revenue growth into consistent profitability and positive free cash flow, maintaining defense and aerospace momentum, and navigating the revenue step-down management has already flagged from a satellite customer.
Fiscal 2026 was strong, with revenue climbing roughly 65% to about $31.5 million and a five-year revenue CAGR near 24%. Management lifted full-year guidance, and the company posted positive adjusted EBITDA in the second half alongside better gross margins and yields. An oversubscribed $10 million raise left the balance sheet with net cash and modest debt, giving more room for scaling and upgrades. Growth in defense and aerospace, including satellite work and new programs, adds a second leg beyond medical endoscopes and micro cameras. The lone Buy-rated $8 target reflects an optimistic view that this small, vertically integrated optics maker can re-rate as it grows.
The company has not yet shown sustainable profits: fiscal 2026 produced a net loss of about $3.6 million, negative EPS, and a fifth straight year of negative free cash flow. Gross margins have narrowed from the mid-30s into the high teens. Management has guided to a roughly 40% sequential revenue drop in the first quarter of fiscal 2027 tied to the satellite customer, with further reduction expected in the second quarter and an adjusted EBITDA loss for the full year. Customer concentration and limited disclosure raise execution questions, while repeated share issuance over five years has diluted holders. Thin coverage, low trading volume, and a five-year share-price lag versus the broader market also weigh on sentiment.
The 52-week high near $6.15 stands as the first notable resistance on any climb toward $8, followed by the all-time high around $7.85, which serves as both a psychological and structural barrier. Support appears near the recent $4.30 to $4.50 area, with the 52-week low of $3.55 as a deeper floor. A sustained move above $6.15 on rising volume would mark an important breakout, while any failure to hold recent lows could leave shares range-bound.
Analyst targets typically look out about 12 months, though a single-target stock offers limited confirmation of that timeframe. Investors should track quarterly results and guidance, especially the satellite-program revenue transition, any progress toward positive EBITDA and free cash flow, new defense and medical wins, and whether additional analysts begin coverage. Balance-sheet health and potential future capital raises also matter given the company’s cash-burn history. From what I see, these quarterly updates will be the clearest signals.
I have found Tickeron’s AI Daily Buy/Sell Signals helpful when following thinly covered names like POCI. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a micro-cap with limited traditional coverage, it offers a way to surface ideas and track trends more efficiently alongside fundamental work. Signals are informational and work best when combined with other research and personal risk considerations.
The $8 objective remains a reference drawn from one Lucid Capital Markets target and the stock’s prior peak near $7.85 rather than any broad consensus. It would require a substantial advance of about 61% from roughly $4.97. The main supports are record revenue growth, raised guidance, a late-year EBITDA inflection, a stronger balance sheet, and defense momentum. The main hurdles are ongoing losses, negative free cash flow, the guided satellite revenue decline and expected fiscal 2027 EBITDA loss, customer concentration, and very limited coverage. Watching quarterly results, the satellite transition, and any move toward profitability will be essential before assessing how realistic the distance to $8 really is.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for POCI moved out of overbought territory on November 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 17 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 85%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on POCI as a result. In 104 of 130 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for POCI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 46 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
POCI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for POCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 21 of 27 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +4.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where POCI advanced for three days, in 113 of 165 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
POCI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 150 cases where POCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (4.964). P/E Ratio (-11.302) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.113) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. POCI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther